Science
Mechanism of Action
This ingredient functions as a multi-pathway corrective agent by competitively inhibiting 5-alpha reductase (Type 1) to reduce DHT-driven oil production and chelating copper at the tyrosinase active site to disrupt pigment formation. It further supports skin clarity through antimicrobial action against P. acnes and suppresses inflammatory signaling via the NF-kappa B pathway, effectively converting to bioactive azelaic acid upon skin contact.
Research
Clinical Evidence
High confidence5%
Key findings
- 01 Facial oil production was reduced by 38% over a 12-week period, matching the efficacy of systemic pharmaceutical treatments.
- 02 When paired with 1% clindamycin, inflammatory lesions decreased by 73% during a 24-week evaluation.
- 03 Melasma severity showed a 44% objective improvement after 16 weeks of consistent application.
Transparency
Dusting Analysis
Because Azelamide MEA is a specialty derivative, it is less commonly used as a 'label claim' filler than its parent acid. However, clinical efficacy is dose-dependent; products containing less than 3% may fail to deliver the significant sebum-control and brightening results observed in trials.
The Formula
Formulation
Stability
Offers superior chemical stability in aqueous and ethanol-based systems compared to pure azelaic acid and does not compromise the integrity of emulsion-based formulas.
Synergies
- Clindamycin
- Niacinamide
- Salicylic Acid
Conflicts
- N-nitrosating agents
- Nitrites
Safety
Safety Profile
Formula must be carefully designed to avoid the formation of N-nitroso compounds, which can lead to nitrosamine contamination.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A highly effective, versatile derivative that solves the formulation limitations of azelaic acid while delivering comparable clinical results for acne and hyperpigmentation.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources